BioSpace News Archive

Revance Therapeutics, Inc., a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, provided a corporate and product pipeline update and shared anticipated milestones for 2020.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today confirmed that it will operate a main floor Exhibitor Booth at The CAMEX - NACS Campus Market Expo 2020 (“NACS Tradeshow”),

ChemoCentryx, Inc., announced that the Company has secured a credit facility of up to $100 million provided by Hercules Capital, Inc., a leader in customized financing for companies in life sciences and technology-related markets.

IntraOp Medical Corporation announced today that Alliant Dermatology in The Villages, Florida has commenced treating skin cancer patients with its latest technology—a Mobetron® electron beam linear accelerator optimized to treat skin lesions.

Tacitus Therapeutics exclusively licenses technology for expansion, differentiation and engineering of hematopoietic stem cells for use in therapeutic applications

Integration of world-class Regulatory and Market Access teams will help companies address Clinical, Regulatory and Market Access strategies in parallel to achieve faster, smarter and patient-led development strategy

Manufacturing veteran Harry Gill joins in newly created role of Senior Vice President, Operations

Evolus, Inc. announced its preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2019 and cash position at December 31, 2019.

SELLAS Life Sciences Group, Inc. announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately $6.5 million of its common shares in a registered direct offering priced at-the-market under Nasdaq rules and warrants to purchase common shares in a concurrent private placement.

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), announced today that its investment company AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has signed a binding term sheet to acquire leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”) as a wholly-owned subsidiary.